Retatrutide dosage: what the trials used.

What retatrutide dosage means here, and what it doesn't

There is no approved dose for retatrutide, which remains a study drug in 2026. Here you can see the trial amounts and where staff placed each shot. The page also explains half-life, the time before a blood level falls by half. The facts come from studies; they aren't steps for use.

This isn't a dosing guide. It doesn't say how much to use, when to take a shot, or when to raise an amount. Study teams made those choices while watching each person. Outside a trial, a research vial may not contain retatrutide at all, and its strength and cleanliness may also be unknown.

If you already have such a vial, this page can't make it safe. A clinic cannot confirm the contents from a label. The effects page explains the risks known so far.

Retatrutide dosage used in the published trials

The first Phase 1b study lasted 12 weeks and followed 72 adults with type 2 diabetes ^[4]. Some groups stayed on one weekly amount, 0.5, 1.5, or 3 mg. Others climbed in steps, which the paper writes as 3/6 mg and 3/6/9/12 mg. The top group, for example, went from 3 to 6, then 9, then 12 mg. On that top dose, people lost 8.96 kg more than people on the dummy shot over 12 weeks.

For obesity, the Phase 2 trial lasted 48 weeks ^[1]. Weekly shots were fixed at 1, 4, 8, or 12 mg after slow increases. Every Phase 2 group raised the amount over the first weeks to reduce gut trouble. At 12 mg, the average loss was 24.2%, against 2.1% on the dummy shot.

For type 2 diabetes, the Phase 2 trial lasted 36 weeks ^[2]. Weekly shots rose in steps from 0.5 mg to 12 mg. At the highest dose, HbA1c, which shows average blood sugar, fell by 2.02%, and weight fell by 16.94% by 36 weeks. Staff placed each shot in body fat beneath the skin.

Every trial placed one weekly shot beneath the skin. Published Phase 2 work tried no tablet and no injection into a vein. That trial record doesn't give you a personal plan.

Retatrutide half life and how long it stays in blood

The Phase 1b trial measured a half-life of about 6 days ^[4]. Half-life names the time before a blood level falls by half. A 6-day half-life means that drop takes about 6 days after a dose. It may take 4-5 half-lives, or 24-30 days, for blood levels to become quite low after stopping.

This slow fall explains why Phase 2 and Phase 3 studies chose a weekly shot. It also means unwanted effects might continue for days, rather than fade within hours. The six-day half-life matters if gut trouble or a pulse rise starts after a dose increase documented in Phase 2. People in Phase 2 had a study team watching them.

A 2025 Biomolecules review explains why retatrutide lasts longer ^[6]. A fatty part helps it attach to albumin, a protein found in blood. That link slows removal from your body. It isn't a reason to pick a dose on your own.

Is retatrutide fda approved, and where review stands

No. In 2026, retatrutide had not been approved by the FDA or any other drug regulator. Phase 3 trials were unfinished, and no request for approval had been filed. The Phase 3 TRIUMPH work covers obesity, type 2 diabetes, heart results, and long-term kidney disease. No filing date came from Eli Lilly.

Approval would require completed Phase 3 work, a full file of results, and FDA review. That review often takes 6-12 months after filing. Forecasts made while the Phase 3 trials were running put approval no sooner than 2027, even if every trial finishes on time. Approval isn't promised, and a hopeful Phase 2 result is not a Phase 3 result.

When will retatrutide be available by prescription

No approved retatrutide product is available, and no approval date was announced in 2026. The Phase 3 TRIUMPH trials are still running. Several trial groups finished signing people up in 2024-2025. Planned finish dates run from late 2025 through 2027, after which the results still need review.

Eli Lilly controls the filing time, and the FDA controls its review. Either can change if a trial raises new questions. A date can't be promised before those steps are done.

Research-labeled retatrutide is sold outside approved care. That material isn't an approved drug, and its contents haven't been proved. This site doesn't help you find or get it.

How to reconstitute retatrutide, and why steps aren't given

To reconstitute means mixing liquid with a freeze-dried powder before a shot. This site gives no retatrutide mixing steps. There is no approved powder for home use.

Retatrutide has been studied only as a trial drug under medical care. No approved way to mix or store it at home exists. A research powder may contain something else, in an unknown amount. Germs that you cannot see may be present too.

Mixing the powder would join several risks at once. You would not know the contents, amount, or cleanliness. In trials, the maker prepared the drug while nurses and doctors watched its use. No other setting has been studied.

Retatrutide availability as a shot, not a pill

All published Phase 1 and Phase 2 studies used a shot placed in body fat just below the skin. No study in people has tested it as a tablet, a nasal spray, or an injection straight into a vein. The once-a-week plan fits the drug's half-life of about six days. That is the time for its blood level to fall by half.

Built from small protein parts, retatrutide is a 39-amino-acid peptide. A fatty part helps it ride on albumin, a protein that travels in the blood. Without special work, the stomach would break down a peptide pill. Lilly hasn't announced a retatrutide pill. It does have a pill form in the works for semaglutide, an older weight and diabetes drug that copies just one gut hormone.